根据新的证据和患者的支持, 英国将重新考虑批准阿尔茨海默病药物lecanemab 和 donanemab 用于NHS. UK to reconsider approving Alzheimer’s drugs lecanemab and donanemab for NHS use, citing new evidence and patient advocacy.

由于制造商的呼吁和患者倡导者的压力日益增加, 英国国家卫生与护理卓越研究所 (NICE) 将重新评估其不批准阿尔茨海默病药物lecanemab 和donanemab用于NHS的决定. The UK’s National Institute for Health and Care Excellence (NICE) will reevaluate its decision not to approve Alzheimer’s drugs lecanemab and donanemab for NHS use, following an appeal from manufacturers and growing pressure from patient advocates. 由于担心成本, 该审查最初在6月份被拒绝了. 此次评估将考虑新证据, 以证明药物能减缓认知衰退的有效性以及更广泛的社会效益, 包括减少护理人员负担. Initially rejected in June due to cost concerns, the review will consider new evidence on the drugs’ effectiveness in slowing cognitive decline and broader societal benefits, including reduced caregiver burden. 虽然脑部胀等风险仍然存在, 但在英国成千上万的早期阿尔茨海默病患者将能够获得治疗方法. If approved, thousands of early-stage Alzheimer’s patients in England could gain access to treatments that may delay symptoms by four to six months, though risks like brain swelling remain. 预计很快的结果可能会影响未来医疗保健资金, 并为评估新型痴呆症治疗树立先例. The outcome, expected soon, could influence future healthcare funding and set a precedent for evaluating new dementia therapies.